SM
BMY.RT

Sabby Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Sabby Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300,000
Closed -$207K – 203
2020
Q4 		$207K Buy
+300,000
New +$639K 0.04% 86

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Sabby Management's BMY.RT Position: Q1 2021 in Review

Sabby Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 300,000 shares — an estimated $207K sold.

Sabby Management first reported a position in BMY.RT in Q4 2020 and held it in 1 quarter. The position peaked at $207K in Q4 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Sabby Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 300,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $207K.
  • Sabby Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2020 and held it in 1 quarter.
  • Sabby Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $207K in Q4 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.